Hepatotoxicity of chemotherapy

Expert Opinion on Drug Safety

Volumn 1, Issue 4, 2002, Pages 339-353

  Sachs, Bradley ^a   Haider, Syed ^a   Balaraman, Rama ^a   Shahab, Nasir ^a   Perry, Michael C ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

cancer therapy; chemotherapy; hepatotoxicity; liver function

Indexed keywords

ANTINEOPLASTIC AGENT;

CLASSIFICATION; ENZYMOLOGY; EXPERT WITNESS; HUMAN; PATHOPHYSIOLOGY; REVIEW; TOXIC HEPATITIS;

ANTINEOPLASTIC AGENTS; EXPERT TESTIMONY; HEPATITIS, TOXIC; HUMANS;

EID: 0042736552     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.4.339     Document Type: Review

References (205)

1. SZNOL M, OHUMA T, HOLLAND JF: Hepatic toxicity of drugs used for hematologic neoplasia. Semin. Liver Dis. (1987) 7:237-256. (Pubitemid 18041649)
2. MCDONALD GB, TIRUMALI N: Intestinal and liver toxicity of antineoplastic drugs. West. J. Med. (1984) 140:250-2591.
3. THALER M, BEHRAM P, SHAWKER TH et al: Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann. Intern. Med. (1988) 108:88-100. (Pubitemid 18081176)
4. ARMITAGE JO, BURNS CP, KENT TH: Liver disease complicating the management of acute leukemia during remission. Cancer (1978) 41:737-742. (Pubitemid 8292585)
5. HARRISON H, MIDDLETON H, CROSBY J et al: Fulminant hepatic failure: an unusual presentation of metastatic liver disease. Gastroenterology (1981) 80:820-825. (Pubitemid 11137768)
6. SCHOEDEL KE, DEKKER A: Hemoperitoneum in the setting of metastatic cancer to the liver. A report of two cases with a review of the literature. Dig. Dis. Sci. (1992) 37:153-154.
7. POCARD M, VINCENT-SOLOMON A, GIRODET J et al: Effects of preoperative chemotherapy on liver function tests after hepatectomy. Hepatogastroenterology (2001) 48:1406-1408. (Pubitemid 33010435)
8. HANASH KA: The nonmetastatic hepatic dysfunction syndrome associated with renal cell carcinoma (hypernephroma): Stauffer's syndrome. Prog. Clin. Biol. Res. (1982) 100:301-316.
9. SUZUKI A, TAKAHASHI T: Liver damage in patients with colony-stimulating- factor-producing tumors. Am. J. Med. (1993) 94:125-132. (Pubitemid 23046436)
10. FARRELL GC: Drug-induced liver disease. Churchill Livingstone, New York (1994).
11. PERRY MC: Chemotherapeutic agents and hepatotoxicity. Semin. Oncol. (1992) 19:551-565.
12. KING P, PERRY MC: Hepatotoxicity of chemotherapy. Oncologist (2001) 6:162-176. (Pubitemid 32323455)
13. WIELA-HOJENSKA A, GORCZYNSKA E, ORZECHOWSKA-JUZWENKO K etal: Metabolic functions of the liver during chemotherapy in children with acute lymphoblastic leukemia. Int. J. Clin. Pharmacol. Ther (2001) 6:246-250. (Pubitemid 32515062)
14. LIANG RH, LOK AS, LAI CL et al.: Hepatitis B infection in patients with lymphomas. Hematol Oncol. (1990) 8:261-270.
15. BENICHOU C: Criteria of drug induced liver disorders: report of an international consensus meeting. J. Hepatol. (1990) 11:272-276.
16. OKEN MM, CREECH RH, TORMEY DC et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. (1982) 5:649-655. (Pubitemid 13149996)
17. HOOFNAGLE JH, DUSHEIKO GM, SCHAFER DF et al.: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. (1982) 96:447-449. (Pubitemid 12139868)
18. FLOWERS MA, HEATHCOTE J, WANLESS I et al: Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low dose methotrexate therapy. Ann. Intern. Med. (1990) 112:381-382. (Pubitemid 20083615)
19. THUNG SN, GERBER MA, KLION F, GILBERT H: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch. Intern. Med. (1985) 145:1313-1314. (Pubitemid 15231923)
20. STROFFOLINI T, ANDRIANI A, BIBAS M, BARLATTANI A: Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma. Ann. Hematol. (2002) 81:48-49. (Pubitemid 36075496)
21. KAWATANI T, TAKEAKI S, TAJIMA F et al.: Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Br. J. Haematol. (2001) 67:45-50. (Pubitemid 32769813)
22. LIM HL, LAU GK, DAVIS GL et al: Cholestatic hepatitis leading to hepatic failure in a patient with organ transmitted hepatitis C virus infection. Gastroenterology (1994) 106:248-251.
23. DESMET VJ: Drug induced liver disease: pathogenetic mechanisms and his to pathological lesions. Eur J. Med. (1993) 2:36-47. (Pubitemid 23042551)
24. PERRY MC: Hepatotoxicity of Chemotherapeutic Agents. In: The Chemotherapy Source Book (3rd edn). Lippincott Williams & Wilkins, Philadelphia (2001):483-493.
25. AUBREY DA: Massive hepatic necrosis after cyclophosphamide. Br. Med. J. (1970) 3:588.
26. WALTERS D, ROBINSON RG, SMITH D et al: Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide. Med. J. Aust. (1972) 2:1070.
27. BACON AM, ROSENBERG SA: Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann. Intern. Med. (1982) 97:62-63.
28. GOLDBERG JW, LIDSKY MD: Cyclophosphamide associated hepatotoxicity. South. Med. J. (1985) 78:222-223.
29. SNYDER LS, HEIGH RL, ANDERSON ML: Cyclophosphamide induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin. Proc. (1993) 68:1203-1204. (Pubitemid 23351070)
30. AMROMIN GD, DELMAN RM SHANBRAN E: Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology (1962) 42:401-410.
31. KOLER RD, FORSGREN AL: Hepatotoxicity due to chlorambucil. Report of a case. JAMA (1958) 167:316-317.
32. LAZARUS H, HERZIG R, GRAHAM-POLE J et al.: Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation in the treatment of refractory cancer. J. Clin. Oncol. (1983) 1:359-367. (Pubitemid 14181196)
33. LEFF R, THOMPSON J, JOHNSON D et al.: Phase II trial of high dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J. Clin. Oncol. (1986) 4:1586-1591. (Pubitemid 17188924)
34. MORRIS LE, GUTHRIE TH: Busulfan induced hepatitis. Am. J. Gastroenterol. (1988) 83:682-683.
35. UNDERWOOD JCE, SHAHANI RT, BLACKBURN EK: Jaundice after treatment of leukemia with busulfan. Br. Med. J. (1971) 1:556-557.
36. DEVITA VT, CARBONE P P, OWENS AH Jr et al.: Clinical trials with 1,3-bis [2-chloroethyl]-nitrosourea, NSC-409962. Cancer Res. (1965) 25:1876-1881.
37. HOOGSTRATEN B, GOTTLIEB JA, CADILI E, TUCKER WG, TALLEY RW, HAUT A: CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study. Cancer (1973) 32:38-43.
38. BRODER LE, CARTER SK: Pancreatic islet cell carcinoma II: results of therapy with streptozotocin in 52 patients. Ann. Intern. Med. (1973) 79:108-118.
39. SCHEIN PS, O'CONNELL MJ, BLOM J et al.: Clinical antitumor activity and toxicity of streptozotocin [NSC-85998]. Cancer (1974) 34:993-1000.
40. EINHORN M, DAVIDSON I: Hepatotoxicity of mercaptopurine. JAMA (1964) 188:802-806.
41. SHOREY J, SCHENKER S, SUKI WN, COMBES B: Hepatotoxicity of mercaptopurine. Arch. Intern. Med. (1968) 122:54-58.
42. PHILLIPS FS, STERNBERG SS, HAMILTON L et al.: The toxic effects of 6-mercaptopurine and related compounds. Ann. NY Acad. Sci. (1957) 60:283-296.
43. FARBER S: Summary of experience with 6-mercaptopurine. Ann. NY Acad. Sci. (1954) 60:412-414.
44. MCILVANIE SK, MACCARTHY JD: Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood (1959) 14 (1):80-90.
45. CLARK PA, HSIA YE, HUNTSMAN RG: Toxic complications of treatment with 6-mercaptopurine. Tw o cases with hepatic necrosis and intestinal ulceration. Br. Med. J. (1960) 1:393-395.
46. ADAMSON PC, ZIMM S, RAGAB AH et al.: A Phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother. Pharmacol. (1990) 26:343-344. (Pubitemid 20271537)
47. PRESENT DH, MELTZER SJ, KRUMHOLTZ MP et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann. Intern. Med. (1989) 111:641-649. (Pubitemid 19259182)
48. KREMER WB: Cytabarine. Ann. Intern. Med. (1975) 82:684-688.
49. BLOOMFIELD CD, LAWRENCE D, ARTHUR DC: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood (1994) 84(Suppl. 1):421. Abstract.
50. ELLISON RR, HOLLAND JF, MARISE W et al.: Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood (1968) 32:507-523.
51. DONEHOWER RC, KARP JE, BURKE PJ: Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat. Rep. (1986) 70:1059-1065. (Pubitemid 16023719)
52. KANTARJIAN H, ESTEY E, PLUNKETT W et al.: Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med. (1986) 81:387-394. (Pubitemid 16003856)
53. BAHNG H, LEE J, AHN J et al.: Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia. Leuk. Res. (2001) 25:213-216. (Pubitemid 32157017)
54. PLUNKETT W, LILIEMARK JO, ESTEY E: Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin. Oncol. (1987) 14:159-166.
55. PIZZUTO J, AVILES A, RAMOS E et al.: Cytosine arabinoside induced liver damage: histopathologic demonstration. Med. Pediatr. Oncol. (1983) 11:287-290. (Pubitemid 13018400)
56. GEORGE CB, MANSOUR RP, REDMOND J et al.: Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer (1984) 54:2360-2362. (Pubitemid 15223373)
57. BATEMAN JR, PUGH RP, CASSIDY FR et al.: 5-Fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer (1971) 28:907-913.
58. NIEDERHUBER JE, GROCHOW LB: Status of infusion chemotherapy for the treatment of liver metastases. Princ. Pract. Oncol. Updates (1989) 3:19.
59. HOHN DC, STAGG R, FRIEDMAN MA et al.: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J. Clin. Oncol. (1989) 7:1646-1654. (Pubitemid 19272834)
60. MARTIN JK, O'CONNELL MJ, WIEAND HS et al.: Intra arterial floxuridine versus systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch. Surg. (1990) 125:1022-1027. (Pubitemid 20249340)
61. DORIA MI JR, SHEPARD KV, LEVIN B et al.: Liver pathology following hepatic arterial infusion chemotherapy: hepatic toxicity with FUDR. Cancer (1986) 58:855-861. (Pubitemid 16035283)
62. CHANG AE, SCHNEIDER PD, SUGARBAKER PH et al.: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann. Surg. (1987) 206:685-693. (Pubitemid 18056182)
63. SHEPARD KV, LEVIN B, KARL RC et al.: Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J. Clin. Oncol. (1985) 3(2):161-169. (Pubitemid 15153756)
64. HOHN D, MELNICK J, STAGG R et al.: Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J. Clin. Oncol. (1985) 3:98-102. (Pubitemid 15187703)
65. ALDRIGHETTI L, MARCELLA A, RONZONI M et al.: Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of fluoxuridine (FudR) for liver metastases from colorectal cancer. Hepatogastroenterology (2001) 48:1302-1307. (Pubitemid 33010412)
66. PATTAVEL J, GARDIOL D, BERGIER N et al.: Fatal liver cirrhosis associated with long term arterial infusion of floxuridine. Lancet (1986) 2(8516):1162-1163. (Pubitemid 17174508)
67. COUNCIL ON DRUGS: Evaluation of two antineoplastic agents: pipobroman (Vercyte) and thioguanine. JAMA (1967) 200:139-140.
68. LEME PR, CREAVEN PJ, ALLEN LM et al.: Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate [NSC 740] in man. Cancer Chemother. Rep. (1975) 59:811-817.
69. COLSKY J, GREENSPAN EM, WARREN TN: Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists. Arch. Pathol. Lab. Med. (1955) 59:198-206.
70. MCINTOSH S, DAVIDSON DL, O'BRIEN RT et al.: Methotrexate hepatotoxicity in children with leukemia. J. Pediatr. (1977) 90:1019-1021.
71. HUTTER RVP, SHIPKEY FH, TAN CTC et al.: Hepatic fibrosis in children with acute leukemia: a complication of therapy. Cancer (1960) 13:288-307.
72. PODURGIEL BJ, MCGILL DB, LUDWIG J et al.: Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin. Proc. (1973) 48:787-792.
73. WEINSTEIN GD: Methotrexate. Ann. Intern. Med. (1977) 86:199-204. (Pubitemid 8042802)
74. WEBER BL, TANYER G, POPLACK DG et al.: Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr. (1987) 5:207-212. (Pubitemid 18000423)
75. GILBERT SC, KLINTMALM G, MENTER A et al.: Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this 'steroid sparing' agent. Arch. Intern. Med. (1990) 150:889-891. (Pubitemid 20122067)
76. ZACHARIAE H, KRAGBALLE K, STOGAARD H: Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br. J. Dermatol. (1980) 102:407-412. (Pubitemid 10147025)
77. RUYMAN FB, MOSIJCZUK A, SAYERS RJ: Hepatoma in a child with methotrexate induced hepatic fibrosis. JAMA (1977) 238:2631-2633. (Pubitemid 8274522)
78. FRIED M, KALRA J, ILARDI C, SAWITSKY A: Hepatocellular carcinoma in a long term survivor of acute lymphocytic leukemia. Cancer (1987) 60:2548-2552. (Pubitemid 17157268)
79. SPRIGGS DR, STOPA E, MAYER RJ et al.: Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. (1986) 46:5953-5958. (Pubitemid 17178010)
80. KAVANAGH JJ, KRAKOFF IH, BODEY G et al.: Phase I study of fludarabine. Eur. J. Cancer Clin. Oncol. (1985) 21(9):1009-1011.
81. WEISS GR, KUHN JG, RIZZO J et al.: A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemother. Pharmacol. (1995) 35:397-402.
82. DOHNER H, HO AD, THALER J et al.: Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Natl. Cancer Inst. (1993) 85(8):658-662. (Pubitemid 23120512)
83. BROGDEN RN, SORKIN EM: Pentostatin: a review of its pharmacology and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs (1993) 46(4):652-677. (Pubitemid 23331064)
84. POPLACK DG, SALLAN SE, RIVERA G et al.: Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. (1981) 41:3343-3346. (Pubitemid 11063599)
85. ROBERT J, GIANNI L: Pharmacokinetics and metabolism of anthracyclines. Cancer Surv. (1993) 17:219.
86. ARACAMONE F, CASSINELLI G, FANTINI G et al.: Adriamycin, 14-hydroxy-daunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. (1969) 11:1101-1110.
87. ZUNINO F, GAMBETTA R, DIMARCO A et al.: Effects of the stereochemical configuration on the interaction of some daunomycin derivatives with DNA. Biochem. Biophys. (1976) 69(3):744-750.
88. GREENE R, COLLINS J, JENKINS J et al.: Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. (1983) 43:3417-3421. (Pubitemid 13061607)
89. MEREDITH MJ, REED DJ: Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU). Biochem. Pharmacol. (1983) 32:1383-1388. (Pubitemid 13088968)
90. REED DJ, FRARISS MW: Glutathione depletion and susceptibility. Pharmacol. Rev. (1984) 36(2):25-33.
91. ITO K, OZASA H, NAGASHIMA Y et al.: Pharmacological preconditioning with doxorubicin. Implications of heme oxygenase-1 induction in doxorubicin-induced hepatic injury in rats. Biochem. Pharmacol. (2001) 62(9):1249-1255. (Pubitemid 33055629)
92. AVILES A, HERRERA J, RAMOS E, AMBRIZ R, AGUIRRE J, PIZZUTO J: Hepatic injury during doxorubicin therapy. Arch. Pathol. Lab. Med. (1984) 108:912-913. (Pubitemid 15202908)
93. KOREN G, BEATTY K, SETO A et al.: The effects of impaired liver function on the elimination of antineoplastic agents. Ann. Pharmacother. (1992) 26(3):363-371.
94. BRENNER DE, WIERNIK PH, WESLEY M et al.: Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer (1984) 53(5):1042-1048. (Pubitemid 14196480)
95. SHENKENBERG TD, VON HOFF DD: Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med. (1986) 105:67-81. (Pubitemid 16097929)
96. PACIUCCI PA, SKLARIN NT: Mitoxantrone and hepatic toxicity. Ann. Intern. Med. (1986) 105:805-806. (Pubitemid 17177004)
97. POVIRK LF: DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat. Res. (1996) 355(1-2):71-89. (Pubitemid 26275505)
98. LAZO JS: Bleomycin. Cancer Chemother. Biol. Response Modif. (1999) 18:39-45.
99. FAGGIOLI P, DE PASCHALE M, TOCCI A et al.: Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica (1997) 82(1):38-42. (Pubitemid 28023485)
100. BLUM RH, CARTER SK, AGRE K: A clinical review of bleomycin. A new antineoplastic agent. Cancer (1973) 31:903-914.
101. DORR RT, BOWDEN GT, ALBERTS DS et al.: Interaction of mitomycin C with mammalian DNA detected by alkaline elution. Cancer Res. (1985) 45:3510-3516. (Pubitemid 15226416)
102. CROOKE ST, BRADNER WT: Mitomycin C: a review. Cancer Treat. Rev. (1976) 3:121-139.
103. ROBERT J, BARBIER P, MANASTER J et al.: Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice. Digestion (1968) 1:229-232.
104. GREEN DM, NORKOOL P, BRESLOW NE et al.: Severe hepatic toxicity after treatment with vincristine and dactinomycin using single dose or divided dose schedules: a report of National Wilm's Tumor Study. J. Clin. Oncol. (1990) 8:1525-1530. (Pubitemid 20301183)
105. TEFFT M, TRAGGIS D, FILLER RM: Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia. Am. J. Roentgenol. Radiat. Ther. Nucl. Med. (1969) 106:750-765.
106. EL SAGHIR NS, HAWKINS KA: Hepatotoxicity following vincristine therapy. Cancer (1984) 54:2006-2008. (Pubitemid 14020637)
107. LOKICH JJ, ZIPOLI TE, PERRI J et al.: Protracted vinblastine infusion. Phase I-II study in malignant melanoma. Am. J. Clin. Oncol. (1984) 7:551.
108. HOHNEKER JA: A summary of vinorelbine (Navelbine) safety data from North American Clinical trials. Semin. Oncol. (1994) 21:42-47 (Pubitemid 24347164)
109. HUIZING MT, SEWBERATH MISSER VH, PIETERS RC et al.: Ta x a n e s: a new class of antitumor agents. Cancer Invest. (1995) 13:381-404.
110. VENOOK AP, EGORIN MJ, ROSNER GL et al.: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J. Clin. Oncol. (1998) 16:1811-1819.
111. TRUDEAU ME, EISENHAUER ES, HIGGINS BP et al.: Docetaxel in patients with metastatic breast cancer: a Phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. (1996) 14:422-428.
112. ALEXANDRE J, BLEUZEN P, BONNETERRE J et al.: Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pre-treated advanced breast cancer patients. J. Clin. Oncol. (2000) 18:562-573. (Pubitemid 30078537)
113. HANJANI P, NOLTE S, SHAHIN MS: Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol. Oncol. (2002) 85(2):278-284. (Pubitemid 34522986)
114. BRAHMER JR, ETTINGER DS: The role of topotecan in the treatment of small cell lung cancer. Oncologist (1998) 3:11-14. (Pubitemid 28106718)
115. ORMOD D, SPENCER CM: Topotecan: a review of its efficacy in small cell lung cancer. Drugs (1999) 58:531-533.
116. BERAN M, ESTEY E, O'BRIEN SM et al.: Results of topotecan single agent therapy in patients with myelodysplastic syndrome and chronic myelomonocytic leukemia. Semin. Hematol. (1999) 368:3-10. (Pubitemid 30030179)
117. BERAN M, ESTEY E, O'BRIEN SM et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndrome and chronic myelomonocytic leukemia. J. Clin. Oncol. (1999) 17:2810-2830.
118. SLICHENMYER WJ, ROWINSKY EK, GROCHOW LB et al.: Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother. Pharmacol. (1994) 34(Suppl.):S53-S57. (Pubitemid 24264045)
119. ROWINSKY EK, KAUFMANN SH, BAKER SD et al.: A Phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clin. Cancer Res. (1996) 2:1921-1930. (Pubitemid 27006623)
120. SALTZ LB, DOUILLARD JY, PIROTTA N et al.: Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist (2001) 6(1):81-91. (Pubitemid 32155818)
121. SIU LL, ROWINSKY EK: A risk benefit assessment of irinotecan in solid tumors. Drug Saf. (1998) 4:783-789.
122. ISSELL BF, CROOKE ST: Etoposide (VP-213). Cancer Treat. Rev. (1979) 6:107-124.
123. TRAN A, HOUSSET C, BOBOC B et al.: Etoposide (VP-213) induced hepatitis. Report of three cases following standard-dose treatments. J. Hepatol. (1991) 12:36-39.
124. WOLFF SN, JOHNSON DH, GRECO FA, WOLFF SN: Etoposide induced hepatic injury: a potential complication of high-dose therapy. Cancer T r e a t. R e p. (1983) 67:1023-1024. (Pubitemid 14208705)
125. CHAN HY, MEYERS FJ, LEWIS JP: High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. Cancer Chemother. Pharmacol. (1987) 20:265-266. (Pubitemid 17163409)
126. PERRY MC, MOERTEL CG, SCHUTT AJ et al.: Phase II studies of dianhydrogalactitol and VP-213. Cancer T r e a t. R e p. (1976) 60:1247-1250.
127. CAVALLI F, TSCHOPP, SONNTAG RW et al.: A case of liver toxicity following cis-diammine dichloroplatinum (II) treatment. Cancer Treat. Rep. (1978) 62:2125-2126. (Pubitemid 9145243)
128. HILL JM, LOEB E, MACLELLAN A et al.: Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemother. Rep. (1975) 59:647-659.
129. POLLERA CF, AMEGLIO F, NARDI M et al.: Cisplatin-induced hepatic toxicity. J. Clin. Oncol. (1987) 5:318-319. Letter.
130. HRUBAN RH, STERNBERG SS, MEYERS P et al.: Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest. (1991) 9:263-268.
131. CHRISTIAN MC: Two toxicities associated with carboplatin use: a. gross hematuria b. hepatic veno-occlusive disease. Department of Health & Human Services Bulletin, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA (1989).
132. MCCLAY E: Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat. R e p. (1987) 71(2):219-220. (Pubitemid 17030164)
133. ASBURY RF, ROSENTHAL SN, DESCALZI ME et al.: Hepatic veno-occlusive disease due to DTIC. Cancer (1980) 47:2670-2674. (Pubitemid 10105326)
134. ERICHSEN C, PEREBBE J: Veno-occlusive liver disease after dacarbazine (DTIC) for melanoma. J. Surg. Oncol. (1984) 27:268-270. (Pubitemid 15179697)
135. HASKELL CM, CANELLOS GP, LEVENTHAL BG et al.: L-Asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N. Engl. J. Med. (1969) 281(19):1028-1034.
136. CAPIZZI RL, BERTINO JR, HANDSCHUMACHER RE: L-Asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann. Intern. Med. (1971) 74(6):893-901.
137. OETTGEN HF, STEPHENSON PA, SCHWARTZ MK et al.: Toxicity of E. Coli L-asparaginase in man. Cancer (1970) 25:253-278.
138. MUSS HB, SPELL N, SCUDIERY D et al.: A Phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin's lymphomas. Invest. New Drugs (1990) 8:125-130. (Pubitemid 20087258)
139. HEDDLE R, CALVERT AF: Hydroxyurea induced hepatitis. Med. J. Aust. (1980) 1:121.
140. THURMAN WG, BLOEDOW C, HOWE CD et al.: A Phase I study of hydroxyurea. Cancer Chemother. Rep. (1963) 29:103-107.
141. MCMASTER K, HENNIGAR G: Drug-induced granulomatous hepatitis. Lab. Investig. (1981) 44(1):61-73.
142. FOWLER R, IMRIE K: Thalidomide-associated hepatitis: a case report. Am. J. Hematol. (2001) 66:300-302. (Pubitemid 32210301)
143. LYSENG-WILLIAMSON K, JARVIS B: Imatinib. Drugs (2001) 61(12):1765-1774.
144. NOVARTUS PHARMACEUTICALS CORPORATION: Gleevec (imatinib mesylate) capsules prescribing information. East Hanover, NJ, USA. May (2001).
145. TALPAZ M, SILVER RT, DRUKER B et al.: A Phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase. Blood (2000) 96(11):469.
146. BROSS PF, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. (2001) 7:1490-1496. (Pubitemid 32708610)
147. MALONEY DG: Preclinical and Phase I and II trials of rituximab. Semin. Oncol. (1999) 26:74-78. (Pubitemid 29523414)
148. QUESADA J, HERSH EM, MANNING J et al.: Treatment of hairy cell leukemia with recombinant alpha interferon. Blood (1985) 68(2):493-497.
149. KANTARJIAN HM, DEISSEROTH A, KURZROCK R et al.: Chronic myelogenous leukemia: a concise update. Blood (1993) 82:691-703. (Pubitemid 23221645)
150. SHEPHERD FA, BEAULIEU R, GELMON K et al.: Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J. Clin. Oncol. (1998) 16:1736-1742.
151. CREAGAN E, AHMANN DL, GREEN SJ: Phase II study of recombinant leukocyte interferon (rIFN-alpha-A) in disseminated malignant melanoma. Cancer (1984) 54:2844-2849. (Pubitemid 15184059)
152. LINDNER DJ, KALVAKOLANU DV, BORDEN EC: Increasing effectiveness of interferon alpha for malignancies. Semin. Oncol. (1997) 24(3 Suppl. 9):S9-99-S9-104.
153. BORDEN EC: Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma. Semin. Oncol. (1994) 21:14-22.
154. KIRKWOOD JM, HARRIS, JE, VERA R et al.: A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. (1985) 45:863-871. (Pubitemid 15161092)
155. KHAN OA, XIA Q, BEVER CT et al.: Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology (1996) 46(6):1639-1643. (Pubitemid 26185786)
156. SMALL EJ, WEISS GR, MALIK UK et al.: Treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J. Sci. Am. (1998) 4(3):162-167.
157. MANI S, POO WJ: Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am. J. Clin. Oncol. (1996) 19(2):149-153. (Pubitemid 26108218)
158. KIRKWOOD JM, ERNSTOFF MS: Interferons in the treatment of human cancer. J. Clin. Oncol. (1986) 4:336-352. (Pubitemid 14107002)
159. QUESADA JR, TALPAZ M, RIOS A et al.: Clinical toxicity of interferons in cancer patients. J. Clin. Oncol. (1986) 4:234-243. (Pubitemid 16161041)
160. GOLDBERG RM, AYOOB M, SIGALS R et al.: Phase I-II trial of lymphoblastoid interferon in metastatic malignant melanoma. Cancer Treat. Rep. (1985) 69:813-816. (Pubitemid 15229420)
161. PERILLO R, TAMBURRO C, REGENSTEIN F et al.: Low dose, titrable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology (1995) 109:908-916.
162. HOOFNAGEL JH, DI BISCEGLIE AM WAGGONER JG et al.: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology (1993) 104:1116-1121. (Pubitemid 23090765)
163. GARCIA-BUEY L, GARCIA-MONZON C, RODRIGUEZ S et al.: Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology (1995) 108:1770-1777.
164. TODROS L, SARACCO G, DURAZZO M et al.: Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver kidney microsomes. Hepatology (1995) 22:1374-1378.
165. FERAY C, SAMUEL D, GIGOU M et al.: An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology (1995) 22:1084-1089.
166. WALTHER EU, HOHLFIELD R: Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology (1999) 53(8):1622-1627. (Pubitemid 29530329)
167. MALAGUARNERA M, RESTUCCIA S, DI FAZIO I et al.: Rapid evolution of chronic viral hepatitis into hepatocellular carcinoma after beta-interferon treatment. Panminerva Med. (1999) 41(1):59-61.
168. ROSENBERG S, LOTZE M, MULE J: New approaches to immunotherapy of cancer using interleukin-2. Ann. Intern. Med. (1988) 108:853-864.
169. NAKAGAWA K, MILLER FN, SIMDS DE et al.: Mechanisms of interleukin-2 induced hepatic toxicity. Cancer Res. (1996) 56:507-510. (Pubitemid 26043647)
170. FISHER B, KEENAN AM, GARRA BS et al.: Interleukin-2 induces profound reversible cholestatsis: a detailed analysis in treated cancer patients. J. Clin. Oncol. (1989) 7(12):1852-1862. (Pubitemid 20014333)
171. HUANG CM, ELIN RJ, RUDDEL M et al.: Changes in laboratory results for cancer patient treated with interleukin-2. Clin. Chem. (1990) 36(3):431-434.
172. KAMMULA US, WHITE DE, ROSENBERG SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer (1998) 83:797-805. (Pubitemid 28387707)
173. WERNER SC, HANGER FM, KRITZLER R: Jaundice during methyl testosterone therapy. Am. J. Med. (1950) 8:325.
174. BERNSTEIN MS, HUNTER RL, HACHNIN S: Hepatoma and peliosis hepatitis in Fanconi's anemia. N. Engl. J. Med. (1971) 284:1135-1136.
175. HENDERSON JT, RICHMOND J, SUMERLING MD: Androgenic-anabolic steroid therapy and hepatocellular carcinoma. Lancet (1973) 1:934.
176. WYSOWSKI DK, FREIMAN JP, TOURTELOT JB et al.: Fatal and nonfatal hepatotoxicity associated with flutamide. Ann. Intern. Med. (1993) 118:860-864. (Pubitemid 23145410)
177. ROSMAN AS, FRISSORA-RODEO C, MARSHALL AT et al.: Cholestatic hepatitis following flutamide. Dig. Dis. Sci. (1993) 38:1756-1759. (Pubitemid 23271435)
178. PINTO HC, BAPISTA A, CAMILO ME et al.: Tamoxifen-associated steatohepatitis-report of three cases. J. Hepatol. (1995) 23:95-97.
179. FOITL DR, HYMAN G, LEFKOWITCH JH: Jaundice and intrahepatic cholestasis following high dose megestrol acetate for breast cancer. Cancer (1989) 63:438-439. (Pubitemid 19038455)
180. ROLLINS BJ: Hepatic veno-occlusive disease. Am. J. Med. (1986) 81:297-306. (Pubitemid 16026124)
181. LEHRNER LM, ENCK RE: Hepatic vein thrombosis after chemotherapy for histiocytoma. Ann. Intern. Med. (1978) 88:575-576. Letter. (Pubitemid 8330320)
182. AYASH LJ, HUNT M, ANTMAN KH et al.: Hepatic veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J. Clin. Oncol. (1990) 8:1699-1706. (Pubitemid 20334325)
183. VASSAL G, HARTMANN O, BENHAMOU E: Busulfan and veno-occlusive disease of the liver. Ann. Intern. Med. (1990) 112:881. (Pubitemid 20182794)
184. SHULMAN HM, MCDONALD GB, MATTHEWS D et al.: An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology (1980) 79:1178-1191. (Pubitemid 11250458)
185. CECI G, BELLA M, MELLISARI M et al.: Fatal hepatic vascular toxicity of DTIC. Cancer (1988) 61:1988-1991.
186. LAZARUS HM, GOTTFREID MR, HERZIG RH et al.: Veno-occlusive disease of liver after high dose mitomycin therapy and autologous bone marrow transplantation. Cancer (1982) 49:1789-1795. (Pubitemid 12153448)
187. DOBBIE M, HOFER S, OBERHOLZER R et al.: Veno-occlusive disease of liver induced by gemzar. Ann. Oncol. (1998) 9:681. Letter. (Pubitemid 28318205)
188. GREEN DM, NORKOOL P, BRESLOW NE et al.: Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: A report from National Wilm's Tumor Study. J. Clin. Oncol. (1990) 8:1525-1530. (Pubitemid 20301183)
189. GILL RA, ONSTAD GR, CARDAMONE JM et al.: Hepatic veno-occlusive disease
190. JOENSUU H, SODERSTROM K, NIKKANEN V: Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. Cancer (1986) 58:1437-1440. (Pubitemid 16016825)
191. WOODS WG, DEHNER LP, NESBIT ME et al.: Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation. Am. J. Med. (1980) 68:285-290. (Pubitemid 10169002)
192. SHULMAN HM, MCDONALD GB, MATTHEWS D et al.: An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology (1980) 79:1178-1191. (Pubitemid 11250458)
193. RIO B, ANDREU G, NICOD A et al.: Thrombocytopenia in veno-occlusive disease after bone marrow transplantation or chemotherapy. Blood (1986) 67:1773-1776. (Pubitemid 16075989)
194. BLOSTEIN MD, PALTIEL OB, THIBAEELT et al.: A comparison of clinical criteria for diagnosis veno-occlusive disease of liver after bone marrow transplantation. Bone Marrow Transplant. (1992) 10:439-443.
195. LASSAU N, LECLERE J, AUPERIN A et al.: Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler ultrasound in 100 patients. Radiology (1997) 204(2):545-552. (Pubitemid 27337510)
196. ATTAL M, HUGUET F, RUBIE H et al.: Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low dose heparin: a prospective randomized trial. Blood (1992) 79:3834-2840.
197. CAHN JY, FLESCH M, BRION A et al.: Prevention of veno-occlusive disease of the liver after bone marrow transplantation. Heparin or no heparin? Blood (1992) 80:2149-2150.
198. CLIFT RA, BIANCO JA, APPPELBAUM FR et al.: A randomized controlled trial of pentoxyphylline for prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood (1993) 82:2025-2030. (Pubitemid 23293983)
199. CZAUDERNA P, CHYCZEWSKI L, LECH K et al.: Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin: preliminary report about hepatoprotective effect of amifostine. Med. Sci. Monit. (2000) 6(3):446-453. (Pubitemid 30432126)
200. BEARMAN SI, SHEN DD, HINDS MS et al.: A Phase I/II study of prostaglandin E1 for prevention of hepatic veno-occlusive disease after bone marrow transplantation. Br. J. Hematol. (1993) 84:727-730.
201. ESSELL JH, SCHROEDER MT, HARMAN GS et al.: Ursodial prophylaxis against hepatic complications of allogeneic bone marrow transplantation. Ann. Intern. Med. (1998) 128:975-981.
202. TERRA SG, SPITZER TR, TSUNODA SM: A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation. Pharmacotherapy (1997) 17(5):929-937. (Pubitemid 27415097)
203. JENNER MJ, MICALLEF IN, ROHATINE AZ et al.: Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide. Med. Oncol. (2000) 17(4):333-336.
204. NORRIS S, CROSBIE O, MCENTEE G et al.: Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Transplantation (1997) 63(10):1521-1524. (Pubitemid 27237462)
205. FIEL MI, SCHIANO TD, KLION FM et al.: Recurring fibro-obliterative venopathy in liver allografts. Am. J. Surg. Pathol. (1999) 23(6):734-737. (Pubitemid 29262839)